Population genomic screening: ethical considerations to guide age at implementation

HIGHLIGHTS

SUMMARY

    (Green et_al, 2013; Marshall et_al, 2020). (Burke et_al, 2013; Committee on Bioethics Committee on Genetics ACMG Genomics SocialEthical and Legal Issues Committee, 2013; Ross et_al, 2013; Clayton et_al, 2014; Murray et_al, 2018). While it might seem straightforward to plan for offering panel testing to patients as they reach the "age of majority" (18 years old in the United_States, when individuals are granted full legal and decision-making capacity; also, the age at which most can consent to medical care), various trade-offs may make implementation later in adulthood preferable. (Goldberg et_al, 2011; Sjouke et_al . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?